<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">
 <list list-type="simple" id="ulist0015">
  <list-item id="u0025">
   <label>•</label>
   <p id="p0075">Chronic viral hepatitis does not appear to increase the risk of a severe course of COVID-19.
    <xref rid="bib1" ref-type="bibr">
     <sup>1</sup>
    </xref> Use telemedicine/local laboratory testing for follow-up visits in patients under antiviral therapy, send follow-up-prescriptions by mail.
   </p>
  </list-item>
  <list-item id="u0030">
   <label>•</label>
   <p id="p0080">Patients with non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH) may suffer from metabolic comorbidities such as diabetes, hypertension and obesity putting them at increased risk of a severe course of COVID-19.</p>
  </list-item>
  <list-item id="u0035">
   <label>•</label>
   <p id="p0085">In patients with autoimmune liver disease, we currently advise against reducing immunosuppressive therapy. Reductions should only be considered under special circumstances (
    <italic>e.g.</italic> medication-induced lymphopenia, or bacterial/fungal superinfection in case of severe COVID-19) after consultation of a specialist.
   </p>
  </list-item>
  <list-item id="u0040">
   <label>•</label>
   <p id="p0090">Emphasis on the importance of vaccination for 
    <italic>Streptococcus pneumoniae</italic> and influenza.
   </p>
  </list-item>
  <list-item id="u0045">
   <label>•</label>
   <p id="p0095">In patients with compensated cirrhosis, consider delaying hepatocellular carcinoma (HCC) surveillance and screening for varices. Non-invasive risk assessment for the presence of varices should be applied for stratification (thrombocyte count or Baveno VI).
    <xref rid="bib18" ref-type="bibr">
     <sup>18</sup>
    </xref> See also section on “
    <xref rid="sec10" ref-type="sec">liver-related diagnostic procedures</xref>”.
   </p>
  </list-item>
 </list>
</p>
